Targeting The MAChR: A Potential Approach To Therapeutic Treatments
Targeting The MAChR: A Potential Approach To Therapeutic Treatments
The Muscarinic Acetylcholine Receptor (mAChR) is a G protein-coupled receptor that is expressed in many tissues and cells in the body. It is a member of the muscarinic acetylcholine receptor subfamily, which includes several other G protein-coupled receptors, including the A1 adenosine receptor, the A2 adenosine receptor, and the M1 muscarinic acetylcholine receptor.
The mAChR is involved in a wide range of physiological processes in the body, including sensory perception, neurotransmission, and regulation of ion channels. It is also a potential drug target, with several studies suggesting that inhibition of the mAChR may have therapeutic benefits in a variety of diseases.
Drugs that target the mAChR have been shown to be effective in treating a range of conditions, including chronic pain, neurodegenerative diseases, and psychiatric disorders. For example, a commonly used drug for the treatment of Alzheimer's disease, donepeptide, is a potent inhibitor of the mAChR.
The mAChR is also an attractive target for drug development due to its relatively high degree of selectivity for G protein-coupled receptors. This means that drugs that target the mAChR are likely to have a more targeted and less invasive effects on other tissues and cells than drugs that target other classes of receptors.
An Overview of the mAChR
The mAChR is a transmembrane receptor that is composed of an extracellular domain, a catalytic domain, and an intracellular domain. The extracellular domain includes a signal- transducing cysteine 鈥嬧?媟esidue, which is involved in the formation of a ligand-protein complex with other G protein-coupled receptors. The catalytic domain contains a catalytic active site that is responsible for the catalytic activity of the receptor. The intracellular domain includes a transmembrane region and a cytoplasmic tail that is involved in the regulation of receptor function.
The mAChR is expressed in a variety of tissues and cells in the body, including the brain, sensory neurons, and skeletal muscles. It is involved in the regulation of a wide range of physiological processes, including sensory perception, neurotransmission, and the regulation of ion channels.
The mAChR is a member of the muscarinic acetylcholine receptor subfamily, which includes several other G protein-coupled receptors, including the A1 adenosine receptor, the A2 adenosine receptor, and the M1 muscarinic acetylcholine receptor. These receptors are involved in a wide range of physiology processes, including the regulation of ion channels, neurotransmission, and the regulation of pain perception.
The mAChR is also involved in the regulation of motor behavior, including the control of muscle tone and the regulation of movement. It is thought to play a role in the regulation of muscle spasticity, and abnormalities in the mAChR have been implicated in a variety of motor neuron disorders.
In addition to its involvement in motor behavior, the mAChR is also involved in the regulation of sensory perception and neurotransmission. It is thought to play a role in the regulation of pain perception, and abnormalities in the mAChR have been implicated in the development of chronic pain.
The mAChR is a potential drug target due to its involvement in a wide range of physiological processes. inhibition of the mAChR has been shown to be effective in treating a variety of conditions, including chronic
Protein Name: Muscarinic Acetylcholine Receptor (mAChR) (nonspecified Subtype)
The "Muscarinic Acetylcholine Receptor (mAChR) Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about Muscarinic Acetylcholine Receptor (mAChR) comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
MUSK | MUSTN1 | MUTYH | MVB12A | MVB12B | MVD | MVK | MVP | MX1 | MX2 | MXD1 | MXD3 | MXD4 | MXI1 | MXRA5 | MXRA5Y | MXRA7 | MXRA8 | MYADM | MYADML | MYADML2 | MYB | MYBBP1A | MYBL1 | MYBL2 | MYBPC1 | MYBPC2 | MYBPC3 | MYBPH | MYBPHL | MYC | MYCBP | MYCBP2 | MYCBP2-AS1 | MYCBPAP | MYCL | MYCL-AS1 | MYCLP1 | MYCN | MYCNOS | MYCNUT | MYCT1 | MYD88 | MYDGF | MYEF2 | Myelin Protein | MYEOV | MYF5 | MYF6 | MYG1 | MYH1 | MYH10 | MYH11 | MYH13 | MYH14 | MYH15 | MYH16 | MYH2 | MYH3 | MYH4 | MYH6 | MYH7 | MYH7B | MYH8 | MYH9 | MYHAS | MYL1 | MYL10 | MYL11 | MYL12A | MYL12B | MYL12BP3 | MYL2 | MYL3 | MYL4 | MYL5 | MYL6 | MYL6B | MYL7 | MYL9 | MYLIP | MYLK | MYLK-AS1 | MYLK-AS2 | MYLK2 | MYLK3 | MYLK4 | MYLKP1 | MYMK | MYMX | MYNN | MYO10 | MYO15A | MYO15B | MYO16 | MYO16-AS1 | MYO16-AS2 | MYO18A | MYO18B | MYO19
